Page 1

VIKING THERAPEUTICS Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Enrollment Continues in Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Phase 1 Study Evaluating VK0214 Achieves Primary and Secondary Objectives ; Phase 1b Proof - of - Concept Trial in X - ALD Patients Underway Quarter - End Cash of $ 228 Million Provides Sufficient Capital to Advance Clinical Programs into Late Stage Development SAN DIEGO , July 28 , 2021 -- Viking Therapeutics , Inc. ( Viking ) ( NASDAQ : VKTX ) , a clinical - stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders , today announced its financial results for the second quarter and six months ended June 30 , 2021 , and provided an update on its clinical pipeline and other corporate developments . Highlights from the Quarter Ended June 30 , 2021 : " During the second quarter of 2021 , we continued to make good progress with our lead program VK2809 for the treatment of NASH and fibrosis . Concurrently , we successfully completed the first clinical study of our VK0214 program , and initiated a Phase 1b study with VK0214 in patients with the adrenomyeloneuropathy form of X - ALD , " stated Brian Lian , Ph.D. , chief executive officer of Viking . " Screening and enrollment continue at a steady pace in our 52 - week Phase 2b VOYAGE study of VK2809 in patients with biopsy - confirmed NASH . Based on data to - date , we believe VK2809 will be a best - in - class therapeutic and are optimistic about its potential in the setting of NASH . With respect to our VK0214 program , last month we reported the results of our first - in - human Phase 1 study of VK0214 in healthy volunteers . The study achieved its primary and secondary objectives , demonstrating encouraging safety and tolerability , along with significant reductions in key lipids . Based on these results , we initiated a Phase 1b clinical trial in patients with adrenomyeloneuropathy and are excited to move this program forward . We expect to report data from both the VOYAGE trial and the Phase 1b study of VK0214 in 2022. Finally , we continue to carefully manage our cash and maintain a strong balance sheet to support our ongoing trials as well as potential future clinical studies . "